CN103751701A - Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoma cell YAC-1 proliferation inhibition drugs - Google Patents
Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoma cell YAC-1 proliferation inhibition drugs Download PDFInfo
- Publication number
- CN103751701A CN103751701A CN201310672109.5A CN201310672109A CN103751701A CN 103751701 A CN103751701 A CN 103751701A CN 201310672109 A CN201310672109 A CN 201310672109A CN 103751701 A CN103751701 A CN 103751701A
- Authority
- CN
- China
- Prior art keywords
- preparation
- extraction
- danshilitong
- cholelithiasis treating
- danshitongli tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 title claims abstract description 14
- 206010025323 Lymphomas Diseases 0.000 title claims abstract description 9
- 230000005764 inhibitory process Effects 0.000 title abstract description 3
- 230000035755 proliferation Effects 0.000 title abstract 2
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 17
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 17
- 238000000874 microwave-assisted extraction Methods 0.000 claims abstract description 11
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 201000001883 cholelithiasis Diseases 0.000 claims description 35
- 238000000605 extraction Methods 0.000 claims description 27
- 239000004863 Frankincense Substances 0.000 claims description 16
- 241001057584 Myrrha Species 0.000 claims description 16
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 5
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 235000019640 taste Nutrition 0.000 claims description 5
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 abstract description 12
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 abstract description 12
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 abstract description 12
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 abstract description 12
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 abstract description 12
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 abstract description 12
- 229940025878 hesperidin Drugs 0.000 abstract description 12
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 abstract description 12
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 1
- 241000092668 Artemisia capillaris Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 241000506964 Dichondra repens Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000219061 Rheum Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 abstract 1
- 241000329195 Sparganium erectum Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000010424 alunite Substances 0.000 abstract 1
- 229910052934 alunite Inorganic materials 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000010446 mirabilite Substances 0.000 abstract 1
- KPZTWMNLAFDTGF-UHFFFAOYSA-D trialuminum;potassium;hexahydroxide;disulfate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KPZTWMNLAFDTGF-UHFFFAOYSA-D 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 20
- 238000000034 method Methods 0.000 description 11
- 239000002775 capsule Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Group | Drug level (mg/ml) | Suppression ratio (%) |
Matched group | 0 | 0 |
1 | 5 | 8.42±7.03 |
2 | 10 | 15.98±8.69* |
3 | 15 | 27.03±10.77** |
4 | 20 | 36.56±12.64** |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310672109.5A CN103751701B (en) | 2013-12-10 | 2013-12-10 | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation suppression lymphoma cell YAC-1 cell proliferation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310672109.5A CN103751701B (en) | 2013-12-10 | 2013-12-10 | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation suppression lymphoma cell YAC-1 cell proliferation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103751701A true CN103751701A (en) | 2014-04-30 |
CN103751701B CN103751701B (en) | 2016-03-02 |
Family
ID=50519128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310672109.5A Expired - Fee Related CN103751701B (en) | 2013-12-10 | 2013-12-10 | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation suppression lymphoma cell YAC-1 cell proliferation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103751701B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988723A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method and application of yin tonifying and calming tablet |
-
2013
- 2013-12-10 CN CN201310672109.5A patent/CN103751701B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988723A (en) * | 2012-10-08 | 2013-03-27 | 李正梅 | Preparation method and application of yin tonifying and calming tablet |
Non-Patent Citations (4)
Title |
---|
俞丽霞等: "《中药药理学》", 31 December 2012, 浙江大学出版社 * |
国家药品监督管理局: "胆石通利胶囊", 《国家药品标准(试行)颁布件》 * |
赵余庆: "《中药及天然产物提取制备关键技术》", 31 January 2012, 中国医药科技出版社 * |
黄红兵: "《抗肿瘤中药临床应用与图谱》", 31 January 2008, 广东科技出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN103751701B (en) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103566023A (en) | Preparation method and application of toothache anti-inflammation tablets | |
CN103655843A (en) | Yikangbuyuan tablet, and preparation method and application thereof | |
CN102988489B (en) | Preparation method and application of nose comforting tablet | |
CN103028005B (en) | Preparation method of anti-lumbago tablet and application thereof | |
CN103656493B (en) | A kind of preparation method of blood stasis dispelling stomach reinforcing sheet and application | |
CN102988550B (en) | Preparation method and application of qinlian tablet | |
CN103800818A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting myeloma cell FO from cell proliferation | |
CN103800816A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting stomach cancer cell MFC from cell proliferation | |
CN102836381A (en) | Preparation method and application of middle calming tablet | |
CN102988611B (en) | Preparation method and application of antihypertension tablet | |
CN103784872B (en) | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation suppression Ascitic Tumor Cells SAC-II C3 cell proliferation thereof | |
CN103751700A (en) | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of lymphoid neoplasm cell P388D1 proliferation inhibition drugs | |
CN103751698A (en) | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of prostatic cancer cell RM-1 proliferation inhibition drugs | |
CN103768514A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting myeloma cell SP2/0 from cell proliferation | |
CN103768517A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting mouse lung cancer cell LLC from cell proliferation | |
CN103690647A (en) | Preparation method of Yikangbuyuan tablet and application of Yikangbuyuan tablet in medicines for inhibiting mouse leukaemia cell L6565 proliferation | |
CN103768516A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting stomach cancer cell MFC from cell proliferation | |
CN103751424A (en) | Preparation method of cold tablet containing Artemisia carvifolia and holly root, and application of cold tablet in teratoma cell F9 cell proliferation inhibition medicines. | |
CN103751701B (en) | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation suppression lymphoma cell YAC-1 cell proliferation thereof | |
CN103751699A (en) | Danshilitong tablet preparation method and application of Danshilitong tablets in preparation of breast tumor cell C127 proliferation inhibition drugs | |
CN103768513B (en) | A kind of preparation method of cholelithiasis treating Danshitongli tablet and the application in preparation inhibition teratocarcinoma cell P19 cell proliferation medicine thereof | |
CN103768509A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting Leydig's cell tumor cell MLTC-1 from cell proliferation | |
CN103768508A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting leukaemia cell P815 from cell proliferation | |
CN103768512A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting lymphomata cell EL4.IL-2 from cell proliferation | |
CN103800819A (en) | Preparation method of Danshitongli tablet and application of Danshitongli tablet in preparing drugs for inhibiting lung cancer cell Hepa1-6 from cell proliferation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Tang Xiaochun Inventor after: Liu Shuzhen Inventor after: Hou Ling Inventor after: Liu Zenghua Inventor after: Li Yan Inventor before: Sun Bo |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160201 Address after: 266500 Huangdao District Hospital of traditional Chinese medicine, Hainan Island Road 158, Huangdao District, Shandong, Qingdao, Qingdao Applicant after: Tang Xiaochun Address before: 250001 Shandong Province, Ji'nan City District Court building 2303 No. 288 Applicant before: JINAN XINQIDIAN MEDICINE SCIENCE & TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160302 Termination date: 20161210 |